WEKO3
アイテム
{"_buckets": {"deposit": "4ceea91a-b8e5-4aec-9b23-9c854661b526"}, "_deposit": {"created_by": 3, "id": "5664", "owners": [3], "pid": {"revision_id": 0, "type": "depid", "value": "5664"}, "status": "published"}, "_oai": {"id": "oai:air.repo.nii.ac.jp:00005664", "sets": ["1482"]}, "author_link": ["15978", "15977", "15976", "15981", "15979", "15980"], "item_10001_biblio_info_7": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2022-03-31", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "3/4", "bibliographicPageEnd": "98", "bibliographicPageStart": "85", "bibliographicVolumeNumber": "48", "bibliographic_titles": [{"bibliographic_title": "秋田医学"}]}]}, "item_10001_description_5": {"attribute_name": "内容記述(抄録)", "attribute_value_mlt": [{"subitem_description": "Stereotactic body radiotherapy (SBRT) uses hypofractionated and more precise irradiation methods, and has the advantages of shorter duration, better outcomes, and fewer side effects than conventional radiotherapy. However, the optimal dosage remains unclear. The purpose of the study was to analyze our preliminary treatment results and safety. We retrospectively analyzed 32 patients (primary cancer, 22 ; metastatic cancer, 10) who underwent SBRT for pulmonary tumors at our hospital from April 2015 to June 2020. SBRT was performed with escalated dose prescriptions (up to 55Gy in 4 fractions/64Gy in 8 fractions for peripheral/central lesions, respectively). We evaluated the local control rate (LC rate), overall survival (OS), progression-free survival (PFS), disease-specific survival (DSS), and adverse events. The target lesions comprised 22 primary lung cancers and 13 metastatic lung cancers. The 2-year LC, OS, PFS, and DSS rates were 82.5%, 68.3%, 50.5%, and 88.0% for primary lung cancer patients and 83.1%, 29.9%, 23.1%, and 48.6% for metastatic lung cancer patients, respectively. Five cases of radiation pneumonitis of grade 2 or higher, one of grade 1 dermatitis and 1 of esophagitis were observed as adverse events. We showed that the treatment outcomes of SBRT for primary and metastatic lung cancers were mostly acceptable.", "subitem_description_type": "Other"}]}, "item_10001_identifier_registration": {"attribute_name": "ID登録", "attribute_value_mlt": [{"subitem_identifier_reg_text": "10.20569/00005977", "subitem_identifier_reg_type": "JaLC"}]}, "item_10001_publisher_8": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "秋田医学会"}]}, "item_10001_source_id_11": {"attribute_name": "NCID", "attribute_value_mlt": [{"subitem_source_identifier": "AN00009294", "subitem_source_identifier_type": "NCID"}]}, "item_10001_source_id_9": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "0386-6106", "subitem_source_identifier_type": "ISSN"}]}, "item_10001_version_type_20": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_970fb48d4fbd8a85", "subitem_version_type": "VoR"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Satoshi, Kumagai"}], "nameIdentifiers": [{"nameIdentifier": "15976", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yuki Wada"}], "nameIdentifiers": [{"nameIdentifier": "15977", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Akira Anbai"}], "nameIdentifiers": [{"nameIdentifier": "15978", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Noriko Takagi"}], "nameIdentifiers": [{"nameIdentifier": "15979", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Eriko Okuyama"}], "nameIdentifiers": [{"nameIdentifier": "15980", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Manabu Hashimoto"}], "nameIdentifiers": [{"nameIdentifier": "15981", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2022-05-02"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "akitai48_3_4(85).pdf", "filesize": [{"value": "741.1 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 741100.0, "url": {"label": "akitai48_3_4(85).pdf", "url": "https://air.repo.nii.ac.jp/record/5664/files/akitai48_3_4(85).pdf"}, "version_id": "749d906c-2b16-4d3f-aaed-59e7c3d785af"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "Stereotactic body radiotherapy", "subitem_subject_scheme": "Other"}, {"subitem_subject": " Stereotactic ablative radiotherapy", "subitem_subject_scheme": "Other"}, {"subitem_subject": " Lung cancer", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Oligometastasis", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "SAFETY AND TREATMENT OUTCOMES OF STEREOTACTIC BODY RADIOTHERAPY FOR PULMONARY TUMORS : A RETROSPECTIVE SINGLE-CENTER STUDY", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "SAFETY AND TREATMENT OUTCOMES OF STEREOTACTIC BODY RADIOTHERAPY FOR PULMONARY TUMORS : A RETROSPECTIVE SINGLE-CENTER STUDY"}]}, "item_type_id": "10001", "owner": "3", "path": ["1482"], "permalink_uri": "https://doi.org/10.20569/00005977", "pubdate": {"attribute_name": "公開日", "attribute_value": "2022-05-02"}, "publish_date": "2022-05-02", "publish_status": "0", "recid": "5664", "relation": {}, "relation_version_is_last": true, "title": ["SAFETY AND TREATMENT OUTCOMES OF STEREOTACTIC BODY RADIOTHERAPY FOR PULMONARY TUMORS : A RETROSPECTIVE SINGLE-CENTER STUDY"], "weko_shared_id": -1}
SAFETY AND TREATMENT OUTCOMES OF STEREOTACTIC BODY RADIOTHERAPY FOR PULMONARY TUMORS : A RETROSPECTIVE SINGLE-CENTER STUDY
https://doi.org/10.20569/00005977
https://doi.org/10.20569/00005977f28ad81e-f403-4285-ae93-32cca7292abb
名前 / ファイル | ライセンス | アクション |
---|---|---|
akitai48_3_4(85).pdf (741.1 kB)
|
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2022-05-02 | |||||
タイトル | ||||||
タイトル | SAFETY AND TREATMENT OUTCOMES OF STEREOTACTIC BODY RADIOTHERAPY FOR PULMONARY TUMORS : A RETROSPECTIVE SINGLE-CENTER STUDY | |||||
言語 | ||||||
言語 | eng | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Stereotactic body radiotherapy | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Stereotactic ablative radiotherapy | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Lung cancer | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Oligometastasis | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
ID登録 | ||||||
ID登録 | 10.20569/00005977 | |||||
ID登録タイプ | JaLC | |||||
著者 |
Satoshi, Kumagai
× Satoshi, Kumagai× Yuki Wada× Akira Anbai× Noriko Takagi× Eriko Okuyama× Manabu Hashimoto |
|||||
内容記述(抄録) | ||||||
内容記述タイプ | Other | |||||
内容記述 | Stereotactic body radiotherapy (SBRT) uses hypofractionated and more precise irradiation methods, and has the advantages of shorter duration, better outcomes, and fewer side effects than conventional radiotherapy. However, the optimal dosage remains unclear. The purpose of the study was to analyze our preliminary treatment results and safety. We retrospectively analyzed 32 patients (primary cancer, 22 ; metastatic cancer, 10) who underwent SBRT for pulmonary tumors at our hospital from April 2015 to June 2020. SBRT was performed with escalated dose prescriptions (up to 55Gy in 4 fractions/64Gy in 8 fractions for peripheral/central lesions, respectively). We evaluated the local control rate (LC rate), overall survival (OS), progression-free survival (PFS), disease-specific survival (DSS), and adverse events. The target lesions comprised 22 primary lung cancers and 13 metastatic lung cancers. The 2-year LC, OS, PFS, and DSS rates were 82.5%, 68.3%, 50.5%, and 88.0% for primary lung cancer patients and 83.1%, 29.9%, 23.1%, and 48.6% for metastatic lung cancer patients, respectively. Five cases of radiation pneumonitis of grade 2 or higher, one of grade 1 dermatitis and 1 of esophagitis were observed as adverse events. We showed that the treatment outcomes of SBRT for primary and metastatic lung cancers were mostly acceptable. | |||||
著者版フラグ | ||||||
出版タイプ | VoR | |||||
出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||
書誌情報 |
秋田医学 巻 48, 号 3/4, p. 85-98, 発行日 2022-03-31 |
|||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 0386-6106 | |||||
NCID | ||||||
収録物識別子タイプ | NCID | |||||
収録物識別子 | AN00009294 | |||||
出版者 | ||||||
出版者 | 秋田医学会 |